-
-
The humanitarian system: politics can not be avoided. Lancet (IF 98.4) Pub Date : 2024-09-21 Shatha Elnakib,Sarah Aly,Yara M Asi,Yusra Ribhi Shawar
-
Liver transplantation plus chemotherapy versus chemotherapy alone in patients with permanently unresectable colorectal liver metastases (TransMet): results from a multicentre, open-label, prospective, randomised controlled trial. Lancet (IF 98.4) Pub Date : 2024-09-21 René Adam,Céline Piedvache,Laurence Chiche,Jean Philippe Adam,Ephrem Salamé,Petru Bucur,Daniel Cherqui,Olivier Scatton,Victoire Granger,Michel Ducreux,Umberto Cillo,François Cauchy,Jean-Yves Mabrut,Chris Verslype,Laurent Coubeau,Jean Hardwigsen,Emmanuel Boleslawski,Fabrice Muscari,Heithem Jeddou,Denis Pezet,Bruno Heyd,Valerio Lucidi,Karen Geboes,Jan Lerut,Pietro Majno,Lamiae Grimaldi,Francis Levi,Maïté
BACKGROUND Despite the increasing efficacy of chemotherapy, permanently unresectable colorectal liver metastases are associated with poor long-term survival. We aimed to assess whether liver transplantation plus chemotherapy could improve overall survival. METHODS TransMet was a multicentre, open-label, prospective, randomised controlled trial done in 20 tertiary centres in Europe. Patients aged 18-65
-
Progressive cervical osteophytosis and dysphagia associated with isotretinoin treatment for rosacea. Lancet (IF 98.4) Pub Date : 2024-09-21 Kamran Naraghi,Helena Marzo-Ortega
-
Cuban doctors in Calabria and the Italian health system crisis. Lancet (IF 98.4) Pub Date : 2024-09-21 Mirko Barone,Giuseppe Massimiliano De Luca,Felice Mucilli,Mario Testini
-
Health-care workers in fragile and conflict-ridden contexts. Lancet (IF 98.4) Pub Date : 2024-09-21 Patricia St Louis,Samuel Lwamushi Makali,Elisabeth Paul
-
Chinese medical legislation: punishment with little protection? Lancet (IF 98.4) Pub Date : 2024-09-21 Rui Zhao,Zhe-An Shen,Yingze Hou
-
Building safe health-care environments in China: urgent challenges. Lancet (IF 98.4) Pub Date : 2024-09-21 Xinyue Yang,Zhiyi Zhang,Zhiqiang Zhang
-
Considerations for the CHH-Lancet Commission on Health, Conflict, and Forced Displacement. Lancet (IF 98.4) Pub Date : 2024-09-21 Khalid El Bairi,Dario Trapani
-
Time for a global human rights treaty for health equity. Lancet (IF 98.4) Pub Date : 2024-09-21 Eric A Friedman,Ruth M Mabry,Richard Obedi,Arachu Castro,Alexandra Finch,John Wangai,Luiz A C Galvao,Eze Eluchie,Gonzalo Hünicken,Miguel Correia,Seth Nimwesiga,Adi Radhakrishnan,Lawrence O Gostin
-
Safe and equitable use of clinical decision support systems. Lancet (IF 98.4) Pub Date : 2024-09-21 Thomas J Hwang,Quoc-Dien Trinh,Elisaveta Sokolov
-
Cuban doctors cannot be the definitive solution for Italy. Lancet (IF 98.4) Pub Date : 2024-09-21 Stefano Rausei,Andrea Giuseppe Bertolini
-
The promise of once-weekly insulins for type 1 diabetes: update on progress. Lancet (IF 98.4) Pub Date : 2024-09-21 Kaitlin M Love,Sue A Brown
-
Stella Kyriakides: using her voice to improve health in Europe. Lancet (IF 98.4) Pub Date : 2024-09-21 Jessamy Bagenal
-
Offline: From Wanless to Darzi-don't miss this opportunity (again). Lancet (IF 98.4) Pub Date : 2024-09-21 Richard Horton
-
-
Liver transplantation in metastatic colorectal cancer: a new standard of care? Lancet (IF 98.4) Pub Date : 2024-09-21 Volker Heinemann,Sebastian Stintzing
-
Mpox global emergency: strengthening African leadership. Lancet (IF 98.4) Pub Date : 2024-09-20 Ibrahim Abubakar,Julius Lutwama,Catherine Kyobutungi,Osman Sankoh
-
The time to address the antibiotic pipeline and access crisis is now. Lancet (IF 98.4) Pub Date : 2024-09-20 Manica Balasegaram,Kevin Outterson,John-Arne Røttingen
-
An urgent case for measles vaccination in Gaza. Lancet (IF 98.4) Pub Date : 2024-09-20 Ronald Waldman,Robert Steinglass,Phillip Nieburg
-
Changing the culture of blood culture. Lancet (IF 98.4) Pub Date : 2024-09-20 Sally Davies,Richard A Marfuggi,Rick A Bright,Steve Brozak,Michael Osterholm
-
Global burden of bacterial antimicrobial resistance 1990-2021: a systematic analysis with forecasts to 2050. Lancet (IF 98.4) Pub Date : 2024-09-13
BACKGROUND Antimicrobial resistance (AMR) poses an important global health challenge in the 21st century. A previous study has quantified the global and regional burden of AMR for 2019, followed with additional publications that provided more detailed estimates for several WHO regions by country. To date, there have been no studies that produce comprehensive estimates of AMR burden across locations
-
Global burden of antimicrobial resistance and forecasts to 2050. Lancet (IF 98.4) Pub Date : 2024-09-13 Samuel Kariuki
-
177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial. Lancet (IF 98.4) Pub Date : 2024-09-13 Michael J Morris,Daniel Castellano,Ken Herrmann,Johann S de Bono,Neal D Shore,Kim N Chi,Michael Crosby,Josep M Piulats,Aude Fléchon,Xiao X Wei,Hakim Mahammedi,Guilhem Roubaud,Hana Študentová,James Nagarajah,Begoña Mellado,Álvaro Montesa-Pino,Euloge Kpamegan,Samson Ghebremariam,Teri N Kreisl,Celine Wilke,Katja Lehnhoff,Oliver Sartor,Karim Fizazi,
BACKGROUND [177Lu]Lu-PSMA-617 (177Lu-PSMA-617) prolongs radiographic progression-free survival and overall survival in patients with metastatic castration-resistant prostate cancer previously treated with androgen receptor pathway inhibitor (ARPI) and taxane therapy. We aimed to investigate the efficacy of 177Lu-PSMA-617 in patients with taxane-naive metastatic castration-resistant prostate cancer
-
177Lu-PSMA-617 for metastatic prostate cancer: aiming for the right spot. Lancet (IF 98.4) Pub Date : 2024-09-13 Joaquin Mateo,Amado J Zurita
-
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet (IF 98.4) Pub Date : 2024-09-13 Domenica Lorusso,Yang Xiang,Kosei Hasegawa,Giovanni Scambia,Manuel Leiva,Pier Ramos-Elias,Alejandro Acevedo,Jakub Cvek,Leslie Randall,Andrea Juliana Pereira de Santana Gomes,Fernando Contreras Mejía,Limor Helpman,Hüseyin Akıllı,Jung-Yun Lee,Valeriya Saevets,Flora Zagouri,Lucy Gilbert,Jalid Sehouli,Ekkasit Tharavichitkul,Kristina Lindemann,Nicoletta Colombo,Chih-Long Chang,Marketa Bednarikova,Hong Zhu
BACKGROUND At the first interim analysis of the phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study, the addition of pembrolizumab to chemoradiotherapy provided a statistically significant and clinically meaningful improvement in progression-free survival in patients with locally advanced cervical cancer. We report the overall survival results from the second interim analysis of this study. METHODS Eligible
-
Hope emerging in the locally advanced cervical cancer landscape. Lancet (IF 98.4) Pub Date : 2024-09-13 Christine Gennigens
-
-
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet (IF 98.4) Pub Date : 2024-09-12 Jonathan D Spicer,Marina C Garassino,Heather Wakelee,Moishe Liberman,Terufumi Kato,Masahiro Tsuboi,Se-Hoon Lee,Ke-Neng Chen,Christophe Dooms,Margarita Majem,Ekkehard Eigendorff,Gastón L Martinengo,Olivier Bylicki,Delvys Rodríguez-Abreu,Jamie E Chaft,Silvia Novello,Jing Yang,Ashwini Arunachalam,Steven M Keller,Ayman Samkari,Shugeng Gao,
BACKGROUND At the first interim analysis of the KEYNOTE-671 trial, adding perioperative pembrolizumab to neoadjuvant chemotherapy significantly improved event-free survival in participants with early-stage non-small-cell lung cancer (NSCLC). We report overall survival and health-related quality of life outcomes from the second interim analysis. METHODS KEYNOTE-671 was a global phase 3 trial done at
-
Improved survival for patients with lung cancer treated with perioperative immunotherapy. Lancet (IF 98.4) Pub Date : 2024-09-12 Carolyn J Presley,Dwight H Owen
-
Direct-to-consumer medical testing: an industry built on fear Lancet (IF 98.4) Pub Date : 2024-09-12 The Lancet
-
BMA members oppose its stance on the Cass Review Lancet (IF 98.4) Pub Date : 2024-09-12 Jacqui Thornton
-
-
Health impacts of fentanyl agreement questioned Lancet (IF 98.4) Pub Date : 2024-09-12 Udani Samarasekera
-
Offline: Breaking the conformity of global health Lancet (IF 98.4) Pub Date : 2024-09-12 Richard Horton
-
-
-
Techquity: digital pathways to reach all people for medical research Lancet (IF 98.4) Pub Date : 2024-09-12 Julia Moore Vogel, Vik Kheterpal, Eric J Topol
-
-
Catheter ablation for atrial fibrillation, atrio-oesophageal fistula, cerebral air embolism, and hyperbaric oxygen therapy Lancet (IF 98.4) Pub Date : 2024-09-12 Renaud Prével MD, Prof Alexandre Boyer MD, Prof Didier Gruson MD, Arthur Orieux MD
-
Beyond bacteria: the growing threat of antifungal resistance Lancet (IF 98.4) Pub Date : 2024-09-12 Norman van Rhijn, Sevtap Arikan-Akdagli, Justin Beardsley, Felix Bongomin, Arunaloke Chakrabarti, Sharon C-A Chen, Tom Chiller, Arnaldo Lopes Colombo, Nelesh P Govender, Ana Alastruey-Izquierdo, Sarah E Kidd, Michaela Lackner, Ruoyu Li, Ferry Hagen
-
Demanding attention to self-medication with antibiotics Lancet (IF 98.4) Pub Date : 2024-09-12 Umadevi Subramanian, Baskar Venkidasamy
-
Antimicrobial resistance in carceral settings Lancet (IF 98.4) Pub Date : 2024-09-12 Samuel Wilk, Jacinda C Abdul-Mutakabbir, Shira Doron, Christina Yen, Justin Berk, Alysse Wurcel
-
Antimicrobial use at end of life: a missing link in public health discourse Lancet (IF 98.4) Pub Date : 2024-09-12 Shila Pandey, Renee Wisniewski, Tiffanny Newman, Susan K Seo, William E Rosa
-
A call for antibiotic stewardship initiatives for dentistry in India Lancet (IF 98.4) Pub Date : 2024-09-12 Deepavalli Arumuganainar
-
Antimicrobial resistance in paediatric blast and crush injuries Lancet (IF 98.4) Pub Date : 2024-09-12 Emily Mayhew, Anthony Bull, Sumudith Jayasuriya
-
Bayesian statistics for clinical research Lancet (IF 98.4) Pub Date : 2024-09-12 Ewan C Goligher MD, Anna Heath PhD, Michael O Harhay PhD
Frequentist and Bayesian statistics represent two differing paradigms for the analysis of data. Frequentism became the dominant mode of statistical thinking in medical practice during the 20th century. The advent of modern computing has made Bayesian analysis increasingly accessible, enabling growing use of Bayesian methods in a range of disciplines, including medical research. Rather than conceiving
-
Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 1 diabetes (QWINT-5): a phase 3 randomised non-inferiority trial Lancet (IF 98.4) Pub Date : 2024-09-10 Richard M Bergenstal MD, Ruth S Weinstock MD, Prof Chantal Mathieu MD, Yukiko Onishi MD, Vishali Vijayanagaram MS, Michelle L Katz MD, Molly C Carr MD, Annette M Chang MD
Insulin efsitora alfa (efsitora) is a once-weekly basal insulin. This phase 3 study aimed to assess the efficacy and safety of efsitora compared with insulin degludec (degludec) in adults with type 1 diabetes.
-
Severe respiratory syncytial virus infection in children: burden, management, and emerging therapies Lancet (IF 98.4) Pub Date : 2024-09-09 Natalie I Mazur MD PhD, Mauricio T Caballero MD MSc, Marta C Nunes PhD
The global burden of respiratory syncytial virus (RSV) lower respiratory tract infection (LRTI) in young children is high. The RSV prevention strategies approved in 2023 will be essential to lowering the global disease burden. In this Series paper, we describe clinical presentation, burden of disease, hospital management, emerging therapies, and targeted prevention focusing on developments and groundbreaking
-
A call for global solidarity and rapid action to control mpox Lancet (IF 98.4) Pub Date : 2024-09-09 Jean B Nachega, Jean‑Jacques Muyembe‑Tamfum, Francine Ntoumi, Placide Mbala‑Kingebeni, Alimuddin Zumla
-
Antimicrobial resistance at a crossroads: the cost of inaction Lancet (IF 98.4) Pub Date : 2024-09-09 Michael Craig, Daniel Jernigan, Kayla Laserson, Stefanie McBride, Jessica Fairbanks, Dawn Sievert, Paige A Armstrong, Heather Ewing Ogle, Howard Zucker
-
Respiratory syncytial virus vaccination and immunoprophylaxis: realising the potential for protection of young children Lancet (IF 98.4) Pub Date : 2024-09-09 Clint Pecenka PhD, Erin Sparrow DrPH, Daniel R Feikin MD, Padmini Srikantiah MD, Delese Mimi Darko PhD, Eric Karikari-Boateng MS, Ranju Baral PhD, Carla Vizzotti MD, Analia Rearte MSc, Rose Jalang'o MBChB, Jessica A Fleming PhD, Prof Federico Martinón-Torres MD PhD, Prof Ruth A Karron MD
The search for safe and efficacious products to prevent severe respiratory syncytial virus (RSV) disease in young infants has lasted more than 60 years. In high-income and middle-income countries, two new products have been authorised: an RSV monoclonal antibody for administration to infants (nirsevimab) and an RSV prefusion F maternal vaccine (RSVpreF [Pfizer, Puurs, Belgium]) for administration to
-
USA pledges $558 million for maternal mortality crisis. Lancet (IF 98.4) Pub Date : 2024-09-07 Bryant Furlow
-
India facing largest Chandipura virus outbreak in 20 years. Lancet (IF 98.4) Pub Date : 2024-09-07 Sharmila Devi
-
The global blood donation index: an imperfect measure of transfusion need. Lancet (IF 98.4) Pub Date : 2024-09-07 Jeremy W Jacobs,Imelda Bates,Claudia S Cohn,Nabajyoti Choudhury,Shirley Owusu-Ofori,Hans Vrielink,Eshan U Patel,Silvano Wendel,Aaron A R Tobian,Evan M Bloch
The optimum number of units of blood and the associated number of blood donors required to meet a given population's needs remain undetermined globally. Typically, a whole blood donation rate of ten donations per 1000 population, at a minimum, is necessary to meet a country's blood needs. This rate is attributed to a WHO recommendation that 1% of a given country's population should donate blood to
-
Safety and efficacy of ATSN-101 in patients with Leber congenital amaurosis caused by biallelic mutations in GUCY2D: a phase 1/2, multicentre, open-label, unilateral dose escalation study. Lancet (IF 98.4) Pub Date : 2024-09-07 Paul Yang,Laura P Pardon,Allen C Ho,Andreas K Lauer,Dan Yoon,Shannon E Boye,Sanford L Boye,Alejandro J Roman,Vivian Wu,Alexandra V Garafalo,Alexander Sumaroka,Malgorzata Swider,Iryna Viarbitskaya,Tomas S Aleman,Mark E Pennesi,Christine N Kay,Kenji P Fujita,Artur V Cideciyan
BACKGROUND Leber congenital amaurosis 1 (LCA1), caused by mutations in GUCY2D, is a rare inherited retinal disease that typically causes blindness in early childhood. The aim of this study was to evaluate the safety and preliminary efficacy of ascending doses of ATSN-101, a subretinal AAV5 gene therapy for LCA1. METHODS 15 patients with genetically confirmed biallelic mutations in GUCY2D were included
-
Congenital syphilis in a 2-month-old infant during Japanese outbreak. Lancet (IF 98.4) Pub Date : 2024-09-07 Tomoaki Hirate,Kaori Kanda,Yumi Ohshima,Kunihiro Shinoda,Nobuyuki Tetsuka
-
Christian Happi: strengthening Africa's capacity in genomics. Lancet (IF 98.4) Pub Date : 2024-09-07 Aarathi Prasad
-
Polygenic risk scores for genomics and population screening. Lancet (IF 98.4) Pub Date : 2024-09-07 Sarah L Perrott,Siddhartha P Kar
-
Violating independence assumption in medical statistics. Lancet (IF 98.4) Pub Date : 2024-09-07 Georgios D Panos